Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C.

Seok Hoo Jeong, Young Kul Jung, Jae Won Yang, Sang Jin Park, Jong Woo Kim, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Sustained virologic response (SVR) for the treatment of chronic hepatitis C (CHC) may differ with ethnicity due to differences in genetic traits. This study evaluated the efficacy of peginterferon and ribavirin, and the association between IL28B genotypes and the treatment efficacy in Korean CHC patients. This was a retrospective cohort study using data from medical records. Eighty-five CHC patients were eligible for assessment of the efficacy of antiviral therapy, and 47 patients were available for an IL28B genetic study, which was performed using the Multiplex tetra-primer PCR method for rs12979860. Overall, the early virologic response rate was 87.1%: 84.9% in HCV genotype 1 and 90.6% in genotype 2. The overall end-of-treatment virologic response rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. The overall SVR rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. For rs12979860, the frequencies of polymorphisms were 89% for the CC type, 11% for the CT type, and 0% for the TT type. Their overall SVR rate was 87% (39/47): 90.5% (38/42) for the CC type and 20% (1/5) for the CT type. For genotype 1, SVR rates were 88% (21/24) for the CC type and 0% (0/4) for the CT type. Multivariate analysis revealed that the IL28B-CC type was a good predictor for SVR. The SVR of the combination therapy in Koreans was higher than that observed in Western countries. This finding might be attributable to the high prevalence of IL28B-CC type among Koreans, which may be a good predictor of SVR.

Original languageEnglish
Pages (from-to)360-367
Number of pages8
JournalClinical and molecular hepatology
Volume18
Issue number4
DOIs
Publication statusPublished - 2012 Dec 1
Externally publishedYes

Fingerprint

Ribavirin
Chronic Hepatitis C
Genotype
Genes
Therapeutics
Sustained Virologic Response
Medical Records
Antiviral Agents
Cohort Studies
Multivariate Analysis
Retrospective Studies
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. / Jeong, Seok Hoo; Jung, Young Kul; Yang, Jae Won; Park, Sang Jin; Kim, Jong Woo; Kwon, Oh Sang; Kim, Yun Soo; Choi, Duck Joo; Kim, Ju Hyun.

In: Clinical and molecular hepatology, Vol. 18, No. 4, 01.12.2012, p. 360-367.

Research output: Contribution to journalArticle

Jeong, Seok Hoo ; Jung, Young Kul ; Yang, Jae Won ; Park, Sang Jin ; Kim, Jong Woo ; Kwon, Oh Sang ; Kim, Yun Soo ; Choi, Duck Joo ; Kim, Ju Hyun. / Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. In: Clinical and molecular hepatology. 2012 ; Vol. 18, No. 4. pp. 360-367.
@article{ce6c0c83966c4d2bb72d8a40e7e5496b,
title = "Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C.",
abstract = "Sustained virologic response (SVR) for the treatment of chronic hepatitis C (CHC) may differ with ethnicity due to differences in genetic traits. This study evaluated the efficacy of peginterferon and ribavirin, and the association between IL28B genotypes and the treatment efficacy in Korean CHC patients. This was a retrospective cohort study using data from medical records. Eighty-five CHC patients were eligible for assessment of the efficacy of antiviral therapy, and 47 patients were available for an IL28B genetic study, which was performed using the Multiplex tetra-primer PCR method for rs12979860. Overall, the early virologic response rate was 87.1{\%}: 84.9{\%} in HCV genotype 1 and 90.6{\%} in genotype 2. The overall end-of-treatment virologic response rate was 81.2{\%}: 75.5{\%} in genotype 1 and 90.6{\%} in genotype 2. The overall SVR rate was 81.2{\%}: 75.5{\%} in genotype 1 and 90.6{\%} in genotype 2. For rs12979860, the frequencies of polymorphisms were 89{\%} for the CC type, 11{\%} for the CT type, and 0{\%} for the TT type. Their overall SVR rate was 87{\%} (39/47): 90.5{\%} (38/42) for the CC type and 20{\%} (1/5) for the CT type. For genotype 1, SVR rates were 88{\%} (21/24) for the CC type and 0{\%} (0/4) for the CT type. Multivariate analysis revealed that the IL28B-CC type was a good predictor for SVR. The SVR of the combination therapy in Koreans was higher than that observed in Western countries. This finding might be attributable to the high prevalence of IL28B-CC type among Koreans, which may be a good predictor of SVR.",
author = "Jeong, {Seok Hoo} and Jung, {Young Kul} and Yang, {Jae Won} and Park, {Sang Jin} and Kim, {Jong Woo} and Kwon, {Oh Sang} and Kim, {Yun Soo} and Choi, {Duck Joo} and Kim, {Ju Hyun}",
year = "2012",
month = "12",
day = "1",
doi = "10.3350/cmh.2012.18.4.360",
language = "English",
volume = "18",
pages = "360--367",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "4",

}

TY - JOUR

T1 - Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C.

AU - Jeong, Seok Hoo

AU - Jung, Young Kul

AU - Yang, Jae Won

AU - Park, Sang Jin

AU - Kim, Jong Woo

AU - Kwon, Oh Sang

AU - Kim, Yun Soo

AU - Choi, Duck Joo

AU - Kim, Ju Hyun

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Sustained virologic response (SVR) for the treatment of chronic hepatitis C (CHC) may differ with ethnicity due to differences in genetic traits. This study evaluated the efficacy of peginterferon and ribavirin, and the association between IL28B genotypes and the treatment efficacy in Korean CHC patients. This was a retrospective cohort study using data from medical records. Eighty-five CHC patients were eligible for assessment of the efficacy of antiviral therapy, and 47 patients were available for an IL28B genetic study, which was performed using the Multiplex tetra-primer PCR method for rs12979860. Overall, the early virologic response rate was 87.1%: 84.9% in HCV genotype 1 and 90.6% in genotype 2. The overall end-of-treatment virologic response rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. The overall SVR rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. For rs12979860, the frequencies of polymorphisms were 89% for the CC type, 11% for the CT type, and 0% for the TT type. Their overall SVR rate was 87% (39/47): 90.5% (38/42) for the CC type and 20% (1/5) for the CT type. For genotype 1, SVR rates were 88% (21/24) for the CC type and 0% (0/4) for the CT type. Multivariate analysis revealed that the IL28B-CC type was a good predictor for SVR. The SVR of the combination therapy in Koreans was higher than that observed in Western countries. This finding might be attributable to the high prevalence of IL28B-CC type among Koreans, which may be a good predictor of SVR.

AB - Sustained virologic response (SVR) for the treatment of chronic hepatitis C (CHC) may differ with ethnicity due to differences in genetic traits. This study evaluated the efficacy of peginterferon and ribavirin, and the association between IL28B genotypes and the treatment efficacy in Korean CHC patients. This was a retrospective cohort study using data from medical records. Eighty-five CHC patients were eligible for assessment of the efficacy of antiviral therapy, and 47 patients were available for an IL28B genetic study, which was performed using the Multiplex tetra-primer PCR method for rs12979860. Overall, the early virologic response rate was 87.1%: 84.9% in HCV genotype 1 and 90.6% in genotype 2. The overall end-of-treatment virologic response rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. The overall SVR rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. For rs12979860, the frequencies of polymorphisms were 89% for the CC type, 11% for the CT type, and 0% for the TT type. Their overall SVR rate was 87% (39/47): 90.5% (38/42) for the CC type and 20% (1/5) for the CT type. For genotype 1, SVR rates were 88% (21/24) for the CC type and 0% (0/4) for the CT type. Multivariate analysis revealed that the IL28B-CC type was a good predictor for SVR. The SVR of the combination therapy in Koreans was higher than that observed in Western countries. This finding might be attributable to the high prevalence of IL28B-CC type among Koreans, which may be a good predictor of SVR.

UR - http://www.scopus.com/inward/record.url?scp=84879495637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879495637&partnerID=8YFLogxK

U2 - 10.3350/cmh.2012.18.4.360

DO - 10.3350/cmh.2012.18.4.360

M3 - Article

C2 - 23323251

AN - SCOPUS:84879495637

VL - 18

SP - 360

EP - 367

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 4

ER -